Pregnancy Risks Linked to Diabetes, Not Weight Loss Drugs, in New Study

The researchers classified pregnancies as having potential accidental exposure to GLP-1 medications if the woman filled a prescription for semaglutide (Ozempic, Wegovy) or liraglutide (Saxenda) during the eight weeks before or after the first day of her last menstrual period. Out of the 756,636 pregnancies examined, only 529 involved prescription records indicating exposure to GLP-1 medications during this period. This relatively small number of exposed pregnancies highlights the rarity of such exposure, despite the widespread use of these drugs for weight loss and diabetes management. [1]

The study accounted for several confounding variables that could influence pregnancy outcomes, including maternal age, BMI, smoking, education, location, and pre-existing diabetes. These adjustments were crucial for isolating the effects of GLP-1 medications from other factors. However, the study’s reliance on prescription records rather than direct confirmation of medication use introduces a limitation, as it assumes high compliance due to the high cost of GLP-1 drugs in Denmark. For example, a 1mg injection of Wegovy or Ozempic (semaglutide) costs approximately €180 and €114, respectively, with subsidies for diabetes treatment reducing the price. [1]

The research found that women prescribed GLP-1 medications for diabetes had a significantly higher risk of preterm birth compared to those not exposed. Specifically, the adjusted odds of premature delivery were 70% higher among women taking liraglutide for diabetes and 84% higher among those taking semaglutide for diabetes. Notably, no such increased risk was found for women using the medications for weight management. This distinction suggests that the underlying condition of diabetes, rather than the medications themselves, may be responsible for the increased risk of preterm birth. [1]

The study’s findings emphasize the need for further research to distinguish between women taking GLP-1 medications for diabetes and those using them for weight management. Combining these groups could obscure important differences in underlying health and pregnancy risks. The researchers also acknowledged that the study’s observational nature means it could identify associations but not establish causation. Additional research is needed before changing existing medical recommendations, as the findings do not justify abandoning current guidance to discontinue GLP-1 medications before a planned pregnancy. [1]

A major study involving more than 750,000 pregnancies has uncovered an important difference in the potential pregnancy risks of popular weight loss medications such as Ozempic and Wegovy (source ID: 1). The study examined whether accidental exposure to GLP-1 medications around conception was associated with complications during pregnancy, focusing on preterm birth, pre-eclampsia, gestational diabetes, and other outcomes (source ID: 1). The results revealed a striking distinction between women prescribed GLP-1 drugs for diabetes and those using them for weight loss (source ID: 1). [1]

Women who unintentionally used these drugs shortly before or during early pregnancy were more likely to give birth prematurely, but only when the medications had been prescribed to treat existing diabetes (source ID: 1). Among women taking the same medications for weight management, researchers found no significant association with premature birth or other pregnancy complications examined in the study (source ID: 1). The findings suggest that diabetes itself, rather than the medications, may be responsible for the increased risk of early delivery (source ID: 1). [1]

The research team used Denmark's nationwide health registries to examine 756,636 pregnancies involving a single baby among 480,231 women (source ID: 1). The researchers classified a pregnancy as having possible accidental exposure to GLP-1 medications if the woman filled a prescription for semaglutide or liraglutide during the eight weeks before or after the first day of her last menstrual period (source ID: 1). This 16-week period included the time when a woman might not yet realize she was pregnant, as well as the early stages of fetal development when major organs begin to form (source ID: 1). [1]

Sources

ScienceDaily Health & Medicine

Prepared with AI assistance from the cited sources.